/
ARTV
$9.58-$0.04 (-0.42%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$467.4M
49M shares
52-week range
$1.48 – $14.53
62% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.29%
Moderate
Price (6 mo)
Loading chart…
Change$-2.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $2.0M | $4.9M | $33.5M | $251.0K | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $2.6M |
| Gross profit | $0 | $2.0M | $4.9M | $33.5M | $251.0K | −$2.6M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $13.8M | $42.4M | $44.0M | $50.3M | $50.3M | $69.5M |
| Operating income | −$18.3M | −$53.3M | −$59.8M | −$30.7M | −$67.3M | −$90.6M |
| EBITDA | −$17.5M | −$71.6M | −$57.2M | −$25.4M | −$56.1M | −$81.3M |
| Net income | −$18.0M | −$71.8M | −$58.4M | −$27.7M | −$58.5M | −$83.9M |
| Net margin | — | -3587.7% | -1184.1% | -82.7% | -23304.0% | — |
| EPS (diluted) | -1.02 | -4.08 | -3.32 | -1.19 | -5.20 | -3.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.67 | $-2.94–$-2.37 | 4 |
| 2027 | $0 | $-2.91 | $-3.55–$-2.44 | 4 |
| 2028 | $2M | $-3.05 | $-4.48–$-2.21 | 5 |
| 2029 | $41M | $-2.58 | $-2.58–$-2.58 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.66
Price
$9.58
Implied downside
-93%
Peer comparison
Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
www.artivabio.com- Employees
- 106
- IPO / List date
- Jul 19, 2024
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ARTV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 80,038 | $515.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARTV yet.
